Jung Min Ahn1, Jung Hwan Suh2, Ah Reum Kwon2, Hyun Wook Chae2, Ho-Seong Kim2. 1. Department of Pediatric Endocrinology, College of Medicine, Gachon University, Seoul, Republic of Korea, anny0805@hanmail.net. 2. Department of Pediatrics, Severance Children's Hospital, Endocrine Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.
Abstract
AIMS: This study aimed to evaluate final adult height (AH) after recombinant human growth hormone (GH) treatment of girls with Turner syndrome (TS) and to elucidate the predicting factors for their growth response. METHODS: We enrolled 73 patients with TS who underwent GH treatment and reached AH and 14 patients who did not undergo treatment. To assess the effectiveness of GH therapy, we evaluated final AH, height gain over the predicted AH, and height gain over the projected AH. In addition, to analyze the factors affecting final AH, we studied correlations between final AH (or height SDS, height gain) and treatment variables. RESULTS: GH therapy was started at a mean age of 8.87 ± 3.73 years, and the treatment duration was 6.47 ± 3.02 years. The patients in the treated group reached a final AH of 152.03 ± 4.66 cm (final AH SDS for the general population: -1.93 ± 1.03) with a gain over projected AH at the start of treatment of 12.21 ± 4.33 cm. The untreated control subjects had a final AH of 143.57 ± 4.06 cm with a gain over projected AH at the first visit of 3.89 ± 3.80 cm. Final AH and AH SDS were positively correlated to height SDS at the start of treatment. Thirty-five patients out of the 73 GH-treated patients (47.9%) attained to a normal range of height for Korean girls. The patients having attained to a normal height range after GH treatment had shown a higher height SDS at the start of GH treatment, a higher mid-parental height SDS, and a younger age at initiation of estrogen. CONCLUSIONS: Our findings demonstrate that GH treatment at an early age is effective in improving the final height SDS and height SDS gain in TS patients. Therefore, GH administration at an early age is important for final height gain.
AIMS: This study aimed to evaluate final adult height (AH) after recombinant humangrowth hormone (GH) treatment of girls with Turner syndrome (TS) and to elucidate the predicting factors for their growth response. METHODS: We enrolled 73 patients with TS who underwent GH treatment and reached AH and 14 patients who did not undergo treatment. To assess the effectiveness of GH therapy, we evaluated final AH, height gain over the predicted AH, and height gain over the projected AH. In addition, to analyze the factors affecting final AH, we studied correlations between final AH (or height SDS, height gain) and treatment variables. RESULTS: GH therapy was started at a mean age of 8.87 ± 3.73 years, and the treatment duration was 6.47 ± 3.02 years. The patients in the treated group reached a final AH of 152.03 ± 4.66 cm (final AH SDS for the general population: -1.93 ± 1.03) with a gain over projected AH at the start of treatment of 12.21 ± 4.33 cm. The untreated control subjects had a final AH of 143.57 ± 4.06 cm with a gain over projected AH at the first visit of 3.89 ± 3.80 cm. Final AH and AH SDS were positively correlated to height SDS at the start of treatment. Thirty-five patients out of the 73 GH-treated patients (47.9%) attained to a normal range of height for Korean girls. The patients having attained to a normal height range after GH treatment had shown a higher height SDS at the start of GH treatment, a higher mid-parental height SDS, and a younger age at initiation of estrogen. CONCLUSIONS: Our findings demonstrate that GH treatment at an early age is effective in improving the final height SDS and height SDS gain in TS patients. Therefore, GH administration at an early age is important for final height gain.
Authors: M B Ranke; C J Partsch; A Lindberg; H G Dorr; M Bettendorf; B P Hauffa; H P Schwarz; O Mehls; S Sander; N Stahnke; H Steinkamp; E Said; W Sippell Journal: Eur J Endocrinol Date: 2002-11 Impact factor: 6.664
Authors: K O Nilsson; K Albertsson-Wikland; J Alm; S Aronson; J Gustafsson; L Hagenäs; A Häger; S A Ivarsson; J Karlberg; B Kriström; C Marcus; C Moell; M Ritzen; T Tuvemo; C Wattsgård; U Westgren; O Westphal; J Aman Journal: J Clin Endocrinol Metab Date: 1996-02 Impact factor: 5.958
Authors: R G Rosenfeld; K M Attie; J Frane; J A Brasel; S Burstein; J F Cara; S Chernausek; R W Gotlin; J Kuntze; B M Lippe; C P Mahoney; W V Moore; P Saenger; A J Johanson Journal: J Pediatr Date: 1998-02 Impact factor: 4.406
Authors: G Massa; C Heinrichs; S Verlinde; M Thomas; J P Bourguignon; M Craen; I François; M Du Caju; M Maes; J De Schepper Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: J Van den Broeck; G G Massa; A Attanasio; A Matranga; J L Chaussain; D A Price; D Aarskog; J M Wit Journal: J Pediatr Date: 1995-11 Impact factor: 4.406